

27 February 2023

Nifty Intraday Chart



Market in Retrospect

Indian equity benchmarks declined in trade for the seventh straight day after opening with losses on Monday as metals, I.T., and auto stocks fell.

Nifty index ended 0.42% lower, ended at 17,393. The broader markets represented by the Nifty 500 Index ended 0.56% lower, ending at 14,549. Among the sectorial indices, Nifty Retail was the top gainer gaining by 2.18%, followed by Nifty Metal gaining by 1%. Nifty Metal was the top loser, losing by 3.89%.

ICICI Bank was the top gainer, gaining by 1.99%, followed by Power Grid and Kotak Bank which gaining by 1.93% & 1.69%. Adani Enterprises was the top loser, losing by 9.28%, followed by Bajaj Auto and UPL losing by 5.46% & 4.06%.

Market Turnover (In Crore) 27-02-2023

Name	Last	Previous
NSE Cash	40326.82	39691.23
NSE F&O	15412842.22	11470785.48
BSE Cash	*NA	5,702.70
BSE F&O	*NA	117.53

FII Derivatives Flow (In Crore) 27-02-2023

Instrument	Purchase	Sale	Net
Index Future	3927.37	4610.04	-682.67
Index Option	1214761.87	1207172.76	7589.11
Stock Future	9853.68	9529.85	323.83
Stock Option	8436.03	8593.28	-157.25

Institutional Flow (In Crore) 27-02-2023

Institution	Purchase	Sale	Net
FII	4315.20	6337.72	2022.52
DII	6621.25	4389.59	2231.66

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
ICICI Bank	1.99	0.50	14422574	10917710
Power Grid	1.93	1.58	13322714	6424008
Kotak Bank	1.69	0.65	2343798	2910279
SBI	1.28	0.49	11048799	13068880
HDFC Life Insurance	1.21	3.79	2587409	3624293

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Infosys	2.67	5.22	4920268	3271018
Tata Steel	3.33	5.56	56217189	27858310
UPL	4.06	6.55	2252550	2020132
Bajaj Auto	5.46	6.76	822866	277790
Adani Enterprises	9.28	26.39	10271008	8116998

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 6:20PM



SMIFS
LIMITED
LEGACY | TRUST | GROWTH

Daily Dossier



Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59288.35	175.58	0.30	2.31	0.07	4.82	6.14
Nifty	17392.70	73.10	0.42	2.53	1.20	6.05	4.41
BSE M Cap	24013.01	165.72	0.69	2.61	1.34	6.18	3.67
BSE S Cap	27232.39	352.20	1.28	2.75	1.42	6.74	2.96
Nifty MC 100	29894.90	208.50	0.69	2.52	1.15	5.36	6.95
BSE Auto	29073.62	445.16	1.51	3.74	2.83	2.25	17.40
BSE Capgoods	33807.50	324.28	0.95	3.42	0.37	0.10	24.37
BSE FMCG	16197.58	124.65	0.76	1.27	0.56	0.86	25.30
BSE Metal	19447.78	273.47	1.39	4.91	8.23	2.99	1.31
BSE Oil&Gas	17158.88	59.14	0.34	1.62	11.92	14.81	1.55
BSE Healthcare	21804.86	191.73	0.87	1.53	3.76	7.87	6.09
BSE Power	3266.94	18.73	0.57	3.26	19.33	28.88	13.90
BSE Realty	3114.57	66.52	2.18	2.96	4.24	12.06	9.59
BSE ConsDur	37439.72	178.94	0.48	2.41	1.25	8.90	11.35
BSE Bank	45704.84	484.71	1.07	0.67	0.11	6.76	9.12
BSE IT	29649.35	591.23	1.96	4.21	0.25	2.41	10.57

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.95	0.01	0.20	3.58	12.78	7.44	101.42
UK	3.79	0.14	3.69	9.31	14.17	21.53	160.40
Brazil	6.57	0.05	0.74	1.33	5.42	7.13	27.65
Japan	0.51	0.00	0.60	0.40	3.26	99.61	140.28
Australia	3.87	0.05	1.31	1.71	8.85	8.39	73.49
India	7.42	0.03	0.46	0.26	0.47	1.66	9.97
Switzerland	1.46	0.00	0.07	1.32	18.03	36.19	354.83
Germany	2.56	0.03	1.06	4.06	14.52	29.89	1009.96

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.85	0.10	0.12	0.14	1.60	1.42	9.06
USD Index	105.06	0.16	0.15	1.15	3.07	0.85	8.74
YUAN	6.95	0.01	0.14	1.37	2.39	3.69	9.23
GBP	1.20	0.00	0.26	0.55	3.29	0.13	10.77
EUR	1.06	0.00	0.11	1.18	2.83	2.13	5.87
YEN	136.25	0.23	0.17	1.47	4.68	1.98	15.60

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	883.00	67.00	8.21	64.13	30.62	33.31	57.47
Baltic Dirty	1338.00	14.00	1.06	4.69	1.13	46.35	16.65
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32816.92	336.99	1.02	2.61	3.42	4.45	3.65
Nasdaq	11394.94	195.46	1.69	3.89	1.95	1.50	16.79
S&P 500	3970.04	42.28	1.05	2.94	2.47	1.39	9.46
FTSE100	7942.45	64.10	0.81	0.89	2.29	6.09	6.05
CAC40	7304.82	117.20	1.63	0.42	2.92	8.82	8.18
DAX	15446.74	236.95	1.56	0.20	1.96	6.23	6.04
Mexico IPC	52686.23	399.48	0.75	2.05	3.81	1.97	0.25
Brazil Bovespa	105798.4	1794.44	1.67	3.47	5.80	2.92	6.49
Russian RTS	929.54	15.37	1.68	1.02	6.33	18.54	0.79
Japan Nikkei	27423.96	29.52	0.11	0.32	0.15	3.04	3.58
Hang Seng	19943.51	66.53	0.33	4.52	12.10	13.49	12.40
Taiwan Index	15503.79	111.62	0.71	0.16	3.82	4.91	12.17
Shanghai Comp	3258.03	9.13	0.28	0.98	0.21	5.04	5.60
KOSPI	2402.64	20.97	0.87	2.14	3.28	1.44	10.24
Malaysia KLCI	1455.50	1.30	0.09	1.22	2.81	2.09	8.56
Jakarta Comp	6854.78	1.80	0.03	0.58	0.64	2.81	0.48
Philippine SE	6599.34	86.56	1.29	2.65	6.28	1.05	8.50
Thai Exch	1627.35	6.67	0.41	1.83	3.21	0.40	3.13

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	76.19	0.14	0.18	0.21	4.39	0.13	16.82
BRENT Crude	82.91	0.25	0.30	1.38	4.04	0.43	0.29
Natural Gas	2.61	0.07	2.59	11.14	9.17	49.88	24.43

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1811.05	0.06	0.00	1.64	6.07	3.20	4.14
Silver(\$/Ounce)	20.73	0.04	0.18	5.00	12.19	4.68	14.61
Aluminium	2285.01	67.74	2.88	2.62	12.78	2.26	33.48
Copper	8689.00	195.99	2.21	2.92	6.48	8.57	12.40
Zinc	2988.25	71.50	2.34	3.16	13.31	2.66	18.38
Lead	2077.75	27.50	1.34	1.05	2.02	1.96	11.39

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	185.80	1.90	1.01	0.03	9.26	12.50	18.97
Cotton	83.89	1.01	1.19	2.93	4.07	5.48	10.94
Sugar	19.80	0.13	0.66	0.00	0.97	7.84	13.86
Wheat	717.00	4.75	0.66	7.63	5.50	11.23	11.01
Soybean	1521.50	2.25	0.15	0.05	1.13	4.95	10.09

India's fertiliser imports up 3.9pc to 19.04 lakh ton in January

The country's fertiliser imports rose by 3.9 per cent to 19.04 lakh tonnes in January this year compared to the year-ago period, according to the Fertiliser Ministry data. The country imported 18.33 lakh tonnes of fertilisers during January 2022. According to the latest data, of the total imports of 19.04 lakh tonne, 10.65 lakh tonnes of urea, 5.62 lakh tonnes of Di-ammonium Phosphate (DAP), 1.14 lakh tonnes of Muriate of Potash (MoP) and 1.63 lakh tonnes of complexes were imported. In the same month of the previous year, the country imported 12.48 lakh tonnes of urea, 2.45 lakh tonnes of DAP and 3.40 lakh tonnes of MoP. The quantity of MoP was for both agriculture and industrial use. The domestic fertiliser production during January this year also rose to 39.14 lakh tonnes when compared with 32.16 lakh tonnes in the year-ago period, the data showed.

Air India's order for 470 jets at list price of \$70 bn

Tata group-owned Air India's order for a record 470 aircraft from Airbus and Boeing Co will be at a list price of \$70 billion, Chief Executive Campbell Wilson said on Monday, as the airline seeks opportunities to expand in long haul international. Air India had, earlier this month, announced provisional deals for 220 planes from Boeing and 250 from Airbus in an order that would eclipse previous records for an order by a single carrier. The airline plans to fund the order with a combination of resources, including internal cash flow, shareholder equity and sale-and-leaseback of aircraft, Wilson told reporters at a press conference. Air India, once considered a world-class airline in India, saw its image tarnish in the mid-2000s due to financial troubles, an ageing fleet and poor service. Air India is inducting 500 cabin crew each month. It said last week that it will hire over 4,200 cabin crew and 900 pilots.

Adani in talks for \$400 million debt against Australian coal port assets

The Adani Group has begun discussions with global credit funds to raise up to \$400 million in debt against assets of a key coal port that makes up a large portion of the conglomerate's Australian exports of the solid fossil fuel from the controversial Carmichael mine. Adani family trust-controlled North Queensland Export Terminal (NQXT) is now being considered to help raise funds for the Adani Group, which has lost nearly \$150 billion in market value since US short-seller Hindenburg Research published a report late last month that alleged 'fraud' and stock price 'manipulation' by the conglomerate.

Granules gets USFDA nod to market generic medication to treat high blood pressure

Drug firm Granules India has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million.

Dr Reddy's to acquire Mayne Pharma US generic portfolio for \$105 million

Dr. Reddy's Laboratories on it entered into a definitive agreement to acquire Mayne Pharma's US generic prescription product portfolio for \$105 million. Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of \$90 million in cash, contingent payments of up to \$15 million, consideration towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.

NPPA fixes retail price of 74 drug formulations

Drug price regulator National Pharmaceutical Pricing Authority on Monday said it has fixed the retail prices of 74 formulations, including the medications to treat diabetes and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has fixed the prices under the Drugs (Price Control) Order 2013 based on the decision of the 109th authority meeting held on February 21 this year. As per the notification, the NPPA has fixed the price of one tablet of Dapagliflozin Sitagliptin and Metformin Hydrochloride (extended-release tablets) at Rs 27.75. Similarly, the drug price regulator has fixed the price of one tablet of blood pressure lowering medication Telmisartan and Bisoprolol Fumarate tablets at Rs 10.92. The ceiling price of one tablet (200mg) of Sodium Valproate has been fixed at Rs 3.20. Similarly, the ceiling price of Filgrastim injection (one vial) has been fixed at Rs 1,034.51. The price of one tablet of Hydrocortisone (20 mg), a steroid, has been fixed at Rs 13.28.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Bharat Agri Fert & Realty Ltd	Corporate meeting effective 28-02-2023
Housing Development Finance Corp Ltd	Corporate meeting effective 28-02-2023
Filtron Engineers Ltd	Corporate meeting effective 28-02-2023

Domestic Events

- India GDP Growth Rate for Q3 2022-23.
- India Infrastructure Output for January 2023.

Global Events

- Japan Industrial Production and Retail Sales for January 2023.
- The U.S. Trade Balance for January 2023.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
